PMID- 24192391
OWN - NLM
STAT- MEDLINE
DCOM- 20141103
LR  - 20220311
IS  - 1552-3365 (Electronic)
IS  - 0363-5465 (Linking)
VI  - 42
IP  - 1
DP  - 2014 Jan
TI  - The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma 
      in osteoarthritis.
PG  - 35-41
LID - 10.1177/0363546513507766 [doi]
AB  - BACKGROUND: Intra-articular (IA) treatment with platelet-rich plasma (PRP) for 
      osteoarthritis (OA) results in improved patient-reported pain and function 
      scores. PURPOSE: To measure the effects of PRP and high molecular weight 
      hyaluronan (HA) on the expression of anabolic and catabolic genes and on the 
      secretion of nociceptive and inflammatory mediators from OA cartilage and 
      synoviocytes. STUDY DESIGN: Controlled laboratory study. METHODS: Synovium and 
      cartilage harvested from patients undergoing total knee arthroplasty were 
      co-cultured with media of PRP or HA. Tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-6 (IL-6), and IL-1beta were measured in the media by enzyme-linked 
      immunosorbent assay. Hyaluronan synthase-2 (HAS-2), matrix metalloproteinase-1 
      (MMP-1), MMP-13, and TNF-alpha genes were measured in synoviocytes by reverse 
      transcription polymerase chain reaction (RT-PCR). Collagen type I alpha1 (COL1A1), 
      COL2A1, aggrecan (ACAN), and MMP-13 gene expression were measured in cartilage by 
      quantitative RT-PCR. RESULTS: Media TNF-alpha concentration was decreased in PRP and 
      HA compared with control cultures (PRP = 6.94 pg/mL, HA = 6.39 pg/mL, control = 
      9.70 pg/mL; P </= .05). Media IL-6 concentration was decreased in HA compared with 
      PRP and control (HA = 5027 pg/mL, PRP = 5899 pg/mL, control = 5613 pg/mL; P </= 
      .05). Media IL-1beta was below detectable concentrations (<0.1 pg/mL) in all 
      samples. Synoviocyte MMP-13 expression was decreased in PRP compared with HA and 
      control (PRP = 10.1, HA = 12.8, control = 13.5; P </= .05). Synoviocyte HAS-2 
      expression was increased in PRP compared with HA and control (PRP = 12.1, HA = 
      9.8, control = 8.7; P </= .05). Cartilage ACAN expression was increased in PRP 
      compared with HA, but neither was different from control (PRP = 8.8, HA = 7.7, 
      control = 7.6; P </= .05); COL1A1 expression was increased in HA compared with PRP, 
      but neither was different from control (PRP = 14.9, HA = 13.5, control = 12.9; P 
      </= .05). Neither platelet nor leukocyte concentration had a significant effect on 
      outcome measurements (gene or protein expression data) in cartilage or 
      synoviocytes (P > .05). CONCLUSION: Both PRP and HA treatments of OA joint 
      tissues result in decreased catabolism, but PRP treatment also resulted in a 
      significant reduction of MMP-13, an increase in HAS-2 expression in synoviocytes, 
      and an increase in cartilage synthetic activity compared with HA. These results 
      indicate that PRP acts to stimulate endogenous HA production and decrease 
      cartilage catabolism. Platelet-rich plasma showed similar effects as HA in the 
      suppression of inflammatory mediator concentration and expression of their genes 
      in synoviocytes and cartilage. CLINICAL RELEVANCE: The antinociceptive and 
      anti-inflammatory activities of PRP support its use in OA joints to reduce pain 
      and modulate the disease process. This study supports further clinical 
      investigations of IA PRP for the treatment of OA.
FAU - Sundman, Emily A
AU  - Sundman EA
AD  - Lisa A. Fortier, DVM, Department of Clinical Sciences, College of Veterinary 
      Medicine, Cornell University, VMC C3-181, Ithaca, NY 14853. laf4@cornell.edu.
FAU - Cole, Brian J
AU  - Cole BJ
FAU - Karas, Vasili
AU  - Karas V
FAU - Della Valle, Craig
AU  - Della Valle C
FAU - Tetreault, Mathew W
AU  - Tetreault MW
FAU - Mohammed, Hussni O
AU  - Mohammed HO
FAU - Fortier, Lisa A
AU  - Fortier LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131105
PL  - United States
TA  - Am J Sports Med
JT  - The American journal of sports medicine
JID - 7609541
RN  - 0 (Aggrecans)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.24.- (Matrix Metalloproteinase 13)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
CIN - Am J Sports Med. 2014 Jun;42(6):NP30-1. PMID: 24879671
CIN - Am J Sports Med. 2014 Jun;42(6):NP31. PMID: 24879672
CIN - Am J Sports Med. 2014 Jun;42(6):NP32. PMID: 24879673
CIN - Am J Sports Med. 2014 Jun;42(6):NP32-3. PMID: 24879674
MH  - Aged
MH  - Aggrecans/genetics
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Cartilage, Articular/*metabolism
MH  - Coculture Techniques
MH  - Collagen/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Hyaluronic Acid/pharmacology
MH  - Interleukin-1beta/metabolism
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Matrix Metalloproteinase 1/metabolism
MH  - Matrix Metalloproteinase 13/genetics/metabolism
MH  - Middle Aged
MH  - Osteoarthritis/metabolism/*therapy
MH  - *Platelet-Rich Plasma
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Synovial Membrane/*metabolism
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
OTO - NOTNLM
OT  - articular cartilage
OT  - biology of cartilage
OT  - growth factors/healing enhancement
OT  - knee
OT  - platelet-rich plasma
OT  - regenerative medicine
OT  - synovium
EDAT- 2013/11/07 06:00
MHDA- 2014/11/05 06:00
CRDT- 2013/11/07 06:00
PHST- 2013/11/07 06:00 [entrez]
PHST- 2013/11/07 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - 0363546513507766 [pii]
AID - 10.1177/0363546513507766 [doi]
PST - ppublish
SO  - Am J Sports Med. 2014 Jan;42(1):35-41. doi: 10.1177/0363546513507766. Epub 2013 
      Nov 5.